HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.9%

Neg 0% Neu 89.9% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.